Gilead Sciences, Inc. Release: European Commission Approves Viread(R) for Chronic Hepatitis B

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the European Commission has granted marketing authorisation for Viread® (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B in all 27 member states of the European Union.

MORE ON THIS TOPIC